Breast oncology Clinical Trials in Nashville, TN

As of July 2026, 73 paid clinical trials are recruiting for Breast oncology in Nashville, Tennessee. Breast oncology research tests new hormone therapies, HER2-targeted agents, PARP inhibitors, antibody-drug conjugates, and immunotherapy combinations across early-stage and metastatic disease. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 17, 2026.

Filter results

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

73 clinical trials for Breast oncology

·Clear filters·↓ Download CSV

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for PIK3CA Mutation

Sites in Nashville +22 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT05216432·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

for Metastatic Breast Cancer

Drug: Palazestrant

Sites in Nashville +13 more locations

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT05508906·Phase 1·Recruiting·Listed Aug 2022

Apply to this trial

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

for Breast Cancer

Sites in Nashville +12 more locations

Sponsor: Processa Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06568692·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

for Advanced Solid Tumor

Sites in Nashville +9 more locations

Sponsor: Circle Pharma

Sex: All·Age: 12+

Code: NCT06577987·Phase 1·Recruiting·Listed Aug 2024

Apply to this trial

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

for Brain Cancer

Sites in Nashville, Memphis +14 more locations

Sponsor: Adela, Inc

Sex: All·Age: 40+·Accepts healthy volunteers

Code: NCT05366881·Recruiting·Listed May 2022

Apply to this trial

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

for Metastatic Breast Cancer

Sites in Nashville +3 more locations

Sponsor: Halda Therapeutics OpCo, Inc.

Sex: Female·Age: 18+

Code: NCT07524855·Phase 1·Recruiting·Listed Apr 2026

Apply to this trial

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

for Advanced Solid Tumors

Sites in Nashville +5 more locations

Sponsor: Accent Therapeutics

Sex: All·Age: 18+

Code: NCT06799065·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

for Hormone Receptor-positive Breast Cancer

Sites in Nashville +5 more locations

Sponsor: Ellipses Pharma

Sex: Female·Age: 18+

Code: NCT05573126·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

for Breast Neoplasms

Sites in Nashville +7 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06797635·Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

for Biliary Tract Cancer

Sites in Nashville +5 more locations

Sponsor: ModeX Therapeutics, An OPKO Health Company

Sex: All·Age: 18+

Code: NCT06239194·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

IKS014 in Advanced Solid Tumors That Express HER2

for Breast Cancer

Sites in Nashville +3 more locations

Sponsor: Iksuda Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT05872295·Phase 1·Recruiting·Listed May 2023

Apply to this trial

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

for Non Small Cell Lung Cancer

Sites in Nashville +7 more locations

Sponsor: Compass Therapeutics

Sex: All·Age: 18+

Code: NCT06150664·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

for Triple Negative Breast Cancer

Sites in Nashville, Germantown +7 more locations

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT06926920·Phase 1, Phase 2·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

for Cancer

Sites in Nashville +5 more locations

Sponsor: Angiex, Inc.

Sex: All·Age: 18+

Code: NCT06440005·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

for Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)

Sites in Nashville +6 more locations

Sponsor: Olema Pharmaceuticals, Inc.

Sex: All·Age: 18+

Code: NCT06784193·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

for Advanced Malignant Neoplasm

Sites in Nashville +3 more locations

Sponsor: AtlasMedx, Incorporated

Sex: All·Age: 18+

Code: NCT04503265·Phase 1, Phase 2·Recruiting·Listed Aug 2020

Apply to this trial

A Study of DM001 in Patients With Advanced Solid Tumors

for Breast Neoplasms

Sites in Nashville +1 more location

Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Sex: All·Age: 18+

Code: NCT06475937·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

for Advanced Solid Tumor

Sites in Nashville +3 more locations

Sponsor: Edgewood Oncology Inc.

Sex: All·Age: 18+

Code: NCT04872166·Phase 1·Recruiting·Listed May 2021

Apply to this trial

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

for Breast Cancer

Sites in Nashville +2 more locations

Sponsor: MBQ Pharma

Sex: All·Age: 21+

Code: NCT06075810·Phase 1·Recruiting·Listed Oct 2023

Apply to this trial

E-Mindfulness Approaches for Living After Breast Cancer

for Breast Cancer

Sites in Nashville, Knoxville +355 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18 - 50

Code: NCT06748222·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

for Anatomic Stage IV Breast Cancer AJCC v8

Sites in Nashville +256 more locations

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT06500455·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for Breast Cancer

Sites in Nashville +46 more locations

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT04893109·Phase 2·Recruiting·Listed May 2021

Apply to this trial

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

for Breast Cancer

Sites in Nashville +6 more locations

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05748834·Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

for Breast Cancer

Sites in Nashville +6 more locations

Sponsor: Massachusetts General Hospital

Sex: Female·Age: 18+

Code: NCT03990896·Phase 2·Recruiting·Listed Jun 2019

Apply to this trial

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

for Breast Cancer

Drug: Atezolizumab

Sites in Nashville +3 more locations

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT04434040·Phase 2·Recruiting·Listed Jun 2020

Apply to this trial

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

for Breast Cancer

Sites in Nashville +6 more locations

Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All·Age: 18+

Code: NCT04841148·Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

for Invasive Mammary Carcinoma

Sites in Nashville +2 more locations

Sponsor: Sonya Reid

Sex: All·Age: 18+

Code: NCT05693766·Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

for Breast Cancer

Sites in Nashville +10 more locations

Sponsor: Ana C Garrido-Castro, MD

Sex: All·Age: 18+

Code: NCT06533826·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

for Breast Cancer

1 location in Nashville

Sponsor: Vanderbilt-Ingram Cancer Center

Sex: Female·Age: 18+·Accepts healthy volunteers

Code: NCT00899301·Recruiting·Listed May 2009

Apply to this trial

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

Sites in Nashville +2 more locations

Sponsor: AstraZeneca

Sex: Female·Age: 18+

Code: NCT07427394·Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

for Non-small Cell Lung Cancer

Sites in Nashville +13 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05877599·Phase 1·Recruiting·Listed May 2023

Apply to this trial

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

for Advanced Breast Cancer

Drug: Camizestrant

Sites in Nashville, Chattanooga +37 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06380751·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

for Breast Cancer

Drug: Durvalumab

Sites in Nashville, Chattanooga +31 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06103864·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Conditions in Breast oncology (Nashville, TN)

Breast cancer· 50 Metastatic breast cancer· 20 Triple-negative breast cancer· 13 HER2-negative breast cancer· 6 HER2-positive breast cancer· 4